Clinical and Pharmacological Aspects of Immunoprophylaxis for Respiratory Syncytial Virus Infection in High-Risk Infants

Publisher： Bentham Science Publishers

E-ISSN： 1875-5453|14|2|216-225

ISSN： 1389-2002

Source： Current Drug Metabolism, Vol.14, Iss.2, 2013-02, pp. : 216-225

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Respiratory Syncytial Virus Immunoprophylaxis: Impact on Epidemiology

By Dougherty N.N.   Meissner H.C.  

Pediatric Drugs, Vol. 2, Iss. 2, 2000-03 ,pp. : 127-132

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children: A UK Analysis

By Nuijten Mark J.C.   Wittenberg Wolfgang   Lebmeier Maximilian  

PharmacoEconomics, Vol. 25, Iss. 1, 2007-01 ,pp. : 55-71

Adis International

Access to resources Recommend Favorite

Emerging drugs for respiratory syncytial virus infection

By Olszewska Wieslawa   Openshaw Peter  

Expert Opinion on Emerging Drugs, Vol. 14, Iss. 2, 2009-06 ,pp. : 207-217

Informa Healthcare

Access to resources Recommend Favorite

Respiratory Syncytial Virus Infection in Elderly Adults

By Falsey Ann R.   Walsh Edward E.  

Drugs & Aging, Vol. 22, Iss. 7, 2005-01 ,pp. : 577-587

Adis International

Access to resources Recommend Favorite

Respiratory Syncytial Virus Infection in Adult Populations

By  

Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 12, Iss. 2, 2012-04 ,pp. : 98-102

Bentham Science Publishers

Access to resources Recommend Favorite